1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Vical plummets on placebo promise in herpes study

 
• By Mandy Jackson

San Diego-based Vical's stock was cut almost in half on 23 June after the company reported that the placebo in a Phase I/II clinical trial outperformed both the monovalent and bivalent forms of its therapeutic genital herpes vaccine by a wide margin. In terms of the trial's primary endpoint, viral shedding decreased 12% for patients treated with the monovalent vaccine, 19% in the study's bivalent arm and 45% in the placebo group.

San Diego-based Vical's stock was cut almost in half on 23 June after the company reported that the placebo in a Phase I/II clinical trial outperformed both the monovalent and bivalent forms of its therapeutic genital herpes vaccine by a wide margin. In terms of the trial's primary endpoint, viral shedding decreased 12% for patients treated with the monovalent vaccine, 19% in the study's bivalent arm and 45% in the placebo group.

Changes in lesion rate and viral load – secondary endpoints in the study – were statistically significant, so longer-term safety...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

Moderna Posts Phase III Efficacy Data For Flu Vaccine

 
• By Joseph Haas

With positive relative efficacy data for its mRNA seasonal flu shot, Moderna hopes to file mRNA-1010 for US approval and refile a COVID-19/flu combo shot that it withdrew in May.

More from Therapy Areas

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.